Abbreviations {#nomen0010}
=============

PD

:   Parkinson's Disease

*SN*

:   *Substantia nigra*

MPTP

:   1-methyl-4-phenyl-1,2,5,6 tetrahydropyridine

GHSR

:   ghrelin receptor

DREADD

:   Designer Receptors Exclusively Activated by Designer Drugs

Drp1

:   dynamin-related protein 1

Mfn

:   mitofusin

Mff

:   mitochondrial fission factor

Fis-1

:   mitochondrial fission 1

OPA-1

:   Dynamin-like 120 kDa protein mitochondrial

DAP

:   2,3-diaminopropionic acid

TH

:   tyrosine hydroxylase

IBA1

:   ionized calcium binding adaptor molecule 1

CD 68

:   glycoprotein cluster of differentiation

CCL-2

:   C-C motif chemokine ligand 2

TNFa

:   Tumor necrosis factor alpha

DHE

:   dihydroethidium

ROS

:   reactive oxygen species

SOD2

:   superoxide dismutase 2

UCP

:   uncoupling protein

DAT

:   dopamine-associated transporter

CNO

:   clozapine-N-oxide

GOAT

:   ghrelin-O-acyl-transferase

RNS

:   reactive nitrogen species

1. Introduction {#sec1}
===============

Parkinson\'s Disease (PD) is a neurodegenerative disease affecting approximately 5--6 million individuals worldwide [@bib1]. This number is expected to escalate to ∼10 million by the year 2030 as the world\'s population rapidly ages [@bib2]. In the United States, more than 1 million individuals have PD, and around 60,000 new cases are diagnosed every year, causing a rapidly expanding social, medical, and financial burden. Clinical features of PD include resting tremor, muscle rigidity, bradykinesia, and postural instability, usually appearing when levels of dopamine (DA) in the dorsal striatum display a 70--80% reduction [@bib3], [@bib4], [@bib5], making it very difficult for PD to be detected at early stages. Parkinson\'s disease etiology is still elusive, and clinical interventions are focused on symptoms management rather than halt of disease progression. Appearing on the clinical scene in the late 60\'s, [l]{.smallcaps}-DOPA administration was the first proposed treatment for PD and is still largely used today, as no major development has occurred regarding effective new treatments [@bib6]. Therefore, a better understanding of how *substantia nigra* (*SN)* DA neurons behave and respond to stimuli that may interfere with disease development will likely support the improvement of current clinical approaches.

Structurally similar to ghrelin, Dln-101 is a proprietary 24--amino acid, acylated peptide derived from a naturally occurring splice variant of the human ghrelin gene. Julst like ghrelin, Dln101, targets the growth hormone secretagogue 1 receptor (GHSR), present in hypothalamic centers controlling energy metabolism and food intake [@bib7], [@bib8], [@bib9] as well as in the SN [@bib10], a brain region where dopamine (DA) cell degeneration leads to PD. Activation of GHSR has been shown to protect *SN* DA neurons against 1-methyl-4-phenyl-1,2,5,6 tetrahydropyridine (MPTP) treatment [@bib11], [@bib12], [@bib13], [@bib14]. The presumable mechanisms underlying GHSR-mediated neuroprotection in rodents include activation of UCP2 and associated decrease in mitochondrial ROS production [@bib12], suppression of the pro-inflammatory cytokines TNFa, IL-6 and IL-1b [@bib15], [@bib16], prevention of MPTP-induced increase in apoptosis-promoting factors caspase-3 and bax, as well as decrease in the anti-apoptotic gene bcl-2 [@bib11], and augmentation of midbrain dopamine neuron electrical activity [@bib17], [@bib18], [@bib19], since there is a growing body of evidence suggesting that the mechanisms that control electrical activity of *SN* DA neurons are not only crucial for regulating dopamine release in the dorsal striatum [@bib20] but also for the survival of these neurons [@bib21].

Finally, it is well established that mitochondria have a central role in substrate oxidation and energy production with broad consequences for whole cellular physiology [@bib22]. The fission/fusion dynamics of mitochondria are critical not only for controlling mitochondrial shape, size, and number, but also for contributing to the dilution and sequestration of mitochondrial damage, impacting directly its function [@bib23], [@bib24]. Fission, for example, facilitates the distribution of mitochondria in response to local demand for ATP, whereas fusion helps to replace damaged mtDNA and to regenerate damaged/depolarized mitochondria [@bib25], [@bib26]. The fission/fusion dynamics are controlled by opposing actions of different dynamin-family members, dynamin-related protein 1 (Drp1) and mitofusins (Mfns), assisted by mitochondrial outer membrane receptors such as mitochondrial fission 1 (Fis-1) and mitochondrial fission factor (Mff) [@bib27], [@bib28]. Dysfunctional mitochondrial fission/fusion dynamics are believed to be central to the pathophysiology of both familial and sporadic PD [@bib29], [@bib30]. These conclusions are supported by the observation of mitochondrial dysfunction and fragmentation in postmortem studies, including altered expression of proteins related to mitochondrial dynamics [@bib31], [@bib32], identification in PD patients of mutations in genes encoding proteins important for mitochondrial dynamics [@bib33], [@bib34], and increased accumulation of mutations in the mitochondrial DNA of *SN* DA neurons with age and PD [@bib35], [@bib36].

Exposure of human and animals to MPTP can reproduce all the characteristic motor and non-motor signs of PD, in addition to mimicking the same responses and side effects to drugs used to treat PD [@bib37], [@bib38]. Anatomically, intoxication with MPTP induces the same selective loss of substantia nigra DA neurons that occurs in PD. In addition, some of the key biochemical changes elicited by MPTP treatment are the same as those identified in idiopathic and genetic forms of PD, such as deficiency in mitochondrial Complex I activity and induction of oxidative stress in DA neurons [@bib39]. The rodent and nonhuman primate MPTP models have been used to develop both symptomatic and neuroprotective treatments for PD.

The aim of this study was to evaluate Dln101 as a potential neuroprotective compound, in comparison with ghrelin, and investigate its GHSR-mediated effects that increase *SN* DA resilience to MPTP. Although Dln101-mediated neuroprotection of *SN* DA cells was equivalent to that of ghrelin, its effect on electrical activity, dopamine release, locomotor behavior, and modulation of mitochondrial dynamics were very distinct despite the requirement of GHSR in mediating both molecules effects.

2. Materials and methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

Otherwise stated, all chemical were purchased from Sigma Aldrich (St. Louis. MO, USA). Dln101 and ghrelin were obtained from Peptides International (Louisville, KY, USA). CNO was obtained from Enzo Life Sciences and Salvinorin B from Cayman chemicals.

2.2. Animals {#sec2.2}
------------

All animal procedures were performed in accordance to the National Institutes of Health Guide for the Care and Use of Laboratory Animals in research and were approved by the Institutional Animal Care and Use Committee of Yale University. All mice were handled once a day for three days prior to the start of experimental procedures for acclimation purposes. Mice harboring the dopamine-associated transporter-cre recombinase transgene (DAT-cre), the tamoxifen-inducible dopamine-associated transporter-cre (iCre-DAT), and the ribotag allele ribotag were all obtained from Jax mice. DAT-cre-ribotag and iCre-DAT-ribotag animals permit, in a cre-dependent fashion (expressed in dopamine neurons), the immunoprecipitation of ribosome-associated mRNA. Mitofusin 2 (mfn2) floxed animals were available in our lab, as previously described [@bib40]. Whole-body GHSR KO mice were also available in our laboratory [@bib41].

2.3. Genotyping {#sec2.3}
---------------

DNA was obtained from toe biopsy. Genomic DNA (gDNA) was extracted and standard PCR was performed using REDExtract-N-Amp™ Kit (Sigma). Cre recombinase, HA-RPL22, and Mfn2 gene presences were assessed according to PCR protocol from Jackson Laboratories. For Cre recombinase transgene, primers did not distinguish heterozygous from homozygous animals. Cre primers used were oIMR1084 (5′-GCGGTCTGGCAGTAAAAACTATC-3′) and oIMR1085 (5′-GTGAAACAGCATTGCTGTCACTT-3′). For HA-RPL22, primers used were 9508 (5′-GGGAGGCTTGCTGGATATG-3′) and 9509 (5′-TTTCCAGACACAGGCTAAGTACAC-3′). For Mfn2, primers were HC106 (5′-GAAGTAGGCAGTCTCCATCG-3′) and HC 107 (5′-AACATCGCTCAGCCTGAACC-3′). For mCAT, primers were 18290 (5′-CGGTGTGGACAACCACTACA-3′) and 18291 (5′-TCAGGAATTCTCTCTCGGTCA-3′).

2.4. Dln101, ghrelin, and MPTP treatment {#sec2.4}
----------------------------------------

Unless otherwise indicated in text, animals were injected with ghrelin or Dln101 for a total of 10 consecutive days, subcutaneous (s.c.), 15 min before the onset of the dark cycle, with either saline (vehicle), ghrelin (15nmoles), or Dln101 (15nmoles) and had their food removed during the dark cycle. *Ad libitum* access to food was re-established in the next morning (8:30-9am). On the seventh day, animals were challenged with MPTP (60 mg/kg, divided in 4 doses, 3--4 h apart). Samples were processed on the morning of day 11.

2.5. Home cage monitoring {#sec2.5}
-------------------------

Mice were left to acclimate in TSE LabMaster home cages for at least 3 days before recording food intake, water intake, and locomotor activity.

2.6. Food intake and body weight measurement {#sec2.6}
--------------------------------------------

All mice were individually caged 5 days before the start of feeding studies to allow the animals to acclimate to their new environment. Animals and food pellets were weighed daily.

2.7. Pharmacokinetic analysis {#sec2.7}
-----------------------------

Pharmacokinetic parameters were determined by non-compartmental analysis using the software package, PK Solutions 2.0 (Summit Research Services). Area under the curve (AUC) values were calculated by the trapezoidal method. Maximal drug concentration in tissue (C~MAX~), time to reach maximal tissue levels (T~MAX~), apparent elimination half-life (2--6 h---sc; 2--4 h---ip), AUC and brain/plasma ratios based on AUC (0--6 h) were evaluated for plasma and brain samples at six different time points following intraperitoneal and subcutaneous administration of ghrelin or Dln101.

2.8. Immunostaining {#sec2.8}
-------------------

Mice were perfused transcardially with ice-cold 0.9% NaCl saline followed by 4% paraformaldehyde, 15% picric acid (vol/vol) in 0.1M phosphate buffer (PB). Brains were removed and fixed in 4% paraformaldehyde for at least 24 h before being cut with the vibratome. Brains 50-μm-thick coronal sections were cut. Before antibody incubation, all sections were blocked in 5% normal goat serum containing 1% BSA, 0.1% glycine and 0.1% [l]{.smallcaps}-lysine to avoid nonspecific antibody binding, then incubated with mouse monoclonal anti-TH (1:3500, Millipore MAb 318) or rabbit polyclonal anti-IBA-1 (1:3000, Wako 019--19741). After overnight incubation at 4 °C, the sections were incubated in respective biotinylated secondary antibodies, and Vectastain ABC kit (Vector Laboratories) or Avidin conjugated to Alexa 488. For visualization after ABC kit, DAB and glucose oxidase were used. All staining was visualized by Axio Scope 1 (Zeiss) and analyzed using ImageJ.

2.9. *In situ* detection of reactive oxygen species {#sec2.9}
---------------------------------------------------

Dihydroethidium (Molecular Probes, Eugene, OR) was used to investigate the local *in situ* production of reactive oxygen species (ROS), because it is specifically oxidized by superoxide to red fluorescent ethidium. An intravenous injection of 200 μl of dihydroedithium (DHE; stock solution, 1 mg/ml in 1% DMSO vehicle) was administered through the tail vein to lightly restrained mice. Three hours after DHE injection, mice were perfused and processed for immunostaining, as described.

2.10. Stereological analysis {#sec2.10}
----------------------------

The *SN* was delineated from −2.54 to −3.88 mm from Bregma according to Paxinos Atlas for the mouse brain [@bib42]. The number of TH^+^ cells in *SN* was estimated counting every other section throughout the rostro-caudal extent of the *SN*.

2.11. Electron microscopy {#sec2.11}
-------------------------

Under deep anesthesia, mice were perfused transcardially with ice-cold 0.9% NaCl saline followed by 4% paraformaldehyde, 15% picric acid (vol/vol), and 0.1% glutaraldehyde (vol/vol) in 0.1M PB, and processed and labeled for immunostaining, except for the addition of a freeze-thaw step to disrupt cellular membranes before the incubation with the primary antibody. Sections were subsequently osmicated and dehydrated, and ultrathin sections were cut on a Leica Ultra-Microtome, collected on Formvar-coated single-slot grids and analyzed with a Tecnai 12 Biotwin transmission electron microscope (TEM - FEI).

2.12. Morphological analysis of mitochondria within *SN* {#sec2.12}
--------------------------------------------------------

Measurements were generated from five to ten randomly acquired TEM images. The morphology of each mitochondrion was analyzed using ImageJ software. Mitochondria were identified by presence of identifiable cristae and distinct double membrane; mitochondria with unclear morphology were excluded from the analysis.

Mitochondrial morphology parameters and terms: "mitochondrial area" = area of every individual mitochondria. "Average mitochondrial area" = summation of the area of every mitochondria divided by the total number of mitochondria, i.e. arithmetic mean."Cytoplasm area" = cell area -- nucleus area. "Mitochondrial cytoplasmic coverage" = summation of the area of every mitochondria divided by the cytoplasm area, in percentage. Two types of analysis were made: using histogram curves to describe and compare the distribution of the mitochondria population between groups and comparing the averages between groups.

2.13. Rotarod {#sec2.13}
-------------

The AccuRotor Rota Rod (Accuscan Instruments, Columbus, OH) apparatus consists of a rotating bar located 20 cm above the floor. On days 1--6, all mice were trained on the rotarod (three trials per day, initial speed = 0 rpm, maximum speed = 25 rpm, time to reach maximum speed = 90 s). The cut-off time on the rotarod was 180 s. The latency to fall from the rotating bar was recorded. The average latency of both last two trials in each day was used for analyzes.

2.14. High performance liquid chromatography (HPLC) determination of neurotransmitters dopamine, serotonin, and their metabolites {#sec2.14}
---------------------------------------------------------------------------------------------------------------------------------

Mice were euthanized, and brain tissue was dissected and snap-frozen using liquid nitrogen. Samples were sonicated in 200 μL of 0.1N perchloric acid and 0.1 ng of 3,4-dihydroxybenzylamine hydrobromide (DHBA, as internal standard); after centrifugation at 14,000 xG for 15 min, the supernatant was filtered through 0.22 μm syringe filter (PALL Corp. PN4454). Tissue level of neurotransmitters was measured by HPLC analysis coupled with electrochemical detection as described [@bib43]. Fast isocratic separation was obtained using a reverse phase Agilent HC-C18 column (5 μm particle size; Agilent Technologies) with the following mobile phase: 30 mM sodium citrate, 13.7 mM sodium monobasic phosphate, 0.025 mM Na~2~EDTA, 0.75 mM sodium octanesulphonate; pH 3.15--3.2, containing 0.6% tetrahydrofuran, 0.1% diethylamine and 6.5% acetonitrile.

2.15. Acute brain slice preparation and electrophysiology {#sec2.15}
---------------------------------------------------------

Coronal brain slices (250 μm) were prepared from 4- to 8-week-old animals for all genotypes tested. The slices were sectioned into ice-cold oxygenated (5% CO~2~, 95% O~2~) dissection buffer (in mM: 87 NaCl, 2.5 KCl, 1.6 NaH~2~PO~4~, 25 NaHCO~3~, 75 sucrose, 10 glucose, 1.3 ascorbic acid, 0.5 CaCl~2~, 7 MgCl~2~), recovered for 15 min at 37 °C in oxygenated artificial cerebrospinal fluid (aCSF) (in mM: 122 NaCl, 3 KCl, 1.2 NaH~2~PO~4~, 26 NaHCO~3~, 20 glucose, 2 CaCl~2~, 1 MgCl~2~, 305--310 mOsm, pH 7.3) and acclimated at room temperature for 10 min before performing electrophysiological recordings. Borosilicate glass electrodes (Sutter Instruments, Novato, CA) were used for whole cell patch clamp recordings. Electrodes were pulled with tip resistance of 2 MΩ, and filled with internal solution (in mM, 120 K-gluconate, 5 KCl, 2 MgCl~2~, 0.05 EGTA, 10 HEPES, 2 Mg-ATP, 0.4 Mg-GTP, 10 creatine phosphate, 290--300 mOsm, pH 7.3). During recordings, coronal brain slices were placed in a room temperature chamber mounted on an Olympus upright microscope (BX50WI) and perfused with oxygenated aCSF. Cells were visualized under differential interference contrast imaging. Data were obtained via a Multiclamp 700B amplifier, low-pass Bessel-filtered at 4 kHz, and digitized on computer disk (Clampex, Axon Instruments).

2.16. Real-time PCR {#sec2.16}
-------------------

Gene expression was investigated using real-time qPCR, performed in 96 or 384-well PCR plates using the Roche 480 LightCycler Thermal Cycler. The real-time PCR reaction mixture contained iTaq SYBR green master mix (BioRad), 0.3 mM primer pairs, and diluted cDNA in a total volume of 10 μl. The mixture was heated initially to 95 °C for 3 min to activate hot-start iTaq DNA polymerase and then followed by 50 cycles with denaturation at 95 °C for 10 s, annealing and extension at 60 °C for 60 s. Samples and standards were run in triplicate. Primers were carefully designed to span exon-exon junction in the mRNA and intron-spanning in the gDNA, when possible. Briefly, NCBI Primer-Blast was used, and gene and mRNA sequences were obtained from NCBI website. Primers were tested for efficiency, specificity, and primer dimer formation using 10-fold dilution curve of cDNA concentration. Additionally, a melt curve protocol designed for increment temperatures of 0.5 °C with a starting temperature of 57 °C and ending at 92 °C was performed at the end of all PCR-reactions. RNA was extracted from target tissues using RNeasy Micro Kit (QIAGEN \#74004) and cDNA was synthesized using Quantitect Reverse Transcription kit (QIAGEN \#205311). Real-time PCR analysis was made using the comparative threshold cycle method (ΔΔCt) with actin as reference gene. Potential reference genes, including actin, cyclophilin A, beta-2 microglobulin, glyceraldehyde-3-phosphate dehydrogenase (gapdh), and riosomal 18S were tested and actin was found to show the least variation among samples. Selected human RNA samples (Kidney, Pancreas, Stomach, Duodenum, Placenta, and non commercial A172 glioblastoma cell line - Brain) were obtained from Stratagene. Primer sets were: Actin F(+)AGTGTGACGTTGACATCCGTA, R(−)GCCAGAGCAGTAATCTCCTTCT; IL1α F(+)CGCTTGAGTCGGCAAAGAAA, R(−)ACTCCCGAAATAAGGCTGCT; IL1β F(+) AAGAGCTTCAGGCAGGCAGTATCA, R(−)ATGAGTCACAGAGGATGGGCTCTT; TNFa F(+)AGACCCTCACACTCAGATCA, R(−)TGTCTTTGAGATCCATGCCG; IFNγ F(+)CCTAGCTCTGAGACAATGAACG, R(−)TTCCACATCTATGCCACTTGAG; IL6 F(+)AGACAAAGCCAGAGTCCTTCAGAG, R(−)TTGGTCCTTAGCCACTCCTTCTGT; IL18 F(+)CGACTTCACTGTACAACCGCAGTA, R(−)CACAGCCAGTCCTCTTACTTCACT; Nlrp3 F(+)ATGCTGCTTCGACATCTCCT, R(−)AACCAATGCGAGATCCTGAC; CD68 F(+)GTGTCTGATCTTGCTAGGACC, R(−)TGTGCTTTCTGTGGCTGTAG; Ccl2 F(+)GGAGAGCTACAAGAGGATCAC, R(−)TGATCTCATTTGGTTCCGATCC; Ccl5 F(+)AGATCTCTGCAGCTGCCCTCA, R(−)GGAGCACTTGCTGCTGGTGTAG; SOD2 F(+)CAATAATGTTGTGTCGGGCG, R(−)CATGATCTGCGCGTTAATGTG; Catalase F(+)CCCTCGGACTTTGGCAAA, R(−)CCAGACTCGAGTATCGCTGACA; Gluthathione Peroxidase F(+)GGAAGCCACATTCCCAGTCA, R(−)GTGCCAAGCCGTAAACACAG; PGC1α F(+)CCCTGCCATTGTTAAGACC, R(−)TGCTGCTGTTCCTGTTTTC; ucp2 F(+) GCATTGGCCTCTACGACTC, R(−)AAGCGGACCTTTACCACATC; ucp3 F(+)GTTCCTTTGCTGCCTATGGA, R(−)TACCCAACCTTGGCTAGACG; ucp4 F(+)CCGCCATTTACAGACACGTAG, R(−)TCCAATGACCGATTTCCAGAG; ucp5 F(+)GAAACCTTTTGTGTATGGCGG, R(−)AACATCGATACTCTGGCCTTG; Fis-1 F(+)AGCTGGTTCTGTGTCCAAG, R(−)TGTTCCTCTTTGCTCCCTTTG; MFF F(+)CTAATCTTTCCTCTGCCCGTG, R(−)GATGAGGATTAGAAGTGGCGG; Drp-1 F(+)TCCCAATTCCATTATCCTCGC, R(−)CATCAGTACCCGCATCCATG; Mfn1 F(+)GGATAATGCAGCCCAGGAG, R(−)GACAGAGATTAGTTTCCAGCCC; Mfn2 F(+)CATCCCCAGTTGTCCTCAAG, R(−)TTCAAGCCGTCTATCATGTCC; OPA-1 F(+)GTGTGCTGGAAATGATTGCTC, R(−)TGGTGAGATCAAATTCCCGAG;

2.17. Viral vectors and stereotaxic injections {#sec2.17}
----------------------------------------------

DAT-cre-ribotag mice were anesthetized with a ketamine/xylazine cocktail and injected into the *SN* (coordinates from Bregma -- AP: 3.6; ML: ±1.4; DV: 4.0 and AP: 3.65; ML: ±1.2; DV: 4.2) with 500 nL of excitatory DREADD virus (rAAV5-hSyn-DIO-hM3Dq-mCherry; 5 × 10^12^ vg/ml), 500 nL of inhibitory DREADD virus (rAAV9-hSyn-DIO-KORD-IRES-mCitrine; 5.3 × 10^12^ vg/ml), or the control virus lacking the DREADD construct rAAV5-hSyn-DIO-mcherry (5 × 10^12^ vg/ml) (UNC Vector Core, Chapel Hill, NC). DREADD receptors are only expressed in cre recombinase-positive cells, and due to spatial localization of the viral injection, this procedure allows the expression of DREADDs exclusively in *SN* DA neurons. Mice were allowed to recover for approximately ten days and then injected daily subcutaneously 15 min before the onset of the dark phase, with either clozapine-N-oxide (CNO, excitatory DREADD agonist 0.3 mg/kg, ENZO Life Sciences) or 0.9% saline vehicle control; or Salvinorin B (inhibitory DREADD agonist 5 mg/kg, Cayman Chemical) or DMSO vehicle control, for seven consecutive days, permitting chemicogenetic excitation of *SN* DA cells with CNO or inhibition of *SN* DA cells with salvinorin B. In addition, for chronic and continuous release of either CNO or Salvinorin B, mice were implanted with subcutaneous osmotic mini-pumps (Alzet). Viral vector placement was assessed via florescent microscopy based on mouse brain atlas landmarks.

2.18. Osmotic mini pump implantation {#sec2.18}
------------------------------------

Before implantation, the Alzet osmotic minipumps (Model 1007D; pumping rate, 0.5 μL/h for seven days) were filled with the appropriate solution and incubated at 37 °C for 24 h for priming and flow stabilization. At the time of the surgery, mice were given intraperitoneal injection of ketamine/xylazine (0.3 mL), and had the pump subcutaneously implanted in the space between the scapulae.

2.19. Statistics {#sec2.19}
----------------

Data are expressed as mean ± SEM unless otherwise indicated. GraphPad Prism 7 was used for all statistical analysis, and we considered p \< 0.05 as statistically significant; labeled as: \* = p \< 0.05, \*\* = p \< 0.01, \*\*\* = p \< 0.001. When ANOVA was performed, post-hoc test was used to compare the mean of each column to the mean of the control column and correcting for multiple comparisons using the Tukey test. When comparing the mean of each column to the mean of every other column, letters (*a,b,c*) were used to indicate differences; unless otherwise indicated in the figure legend.

3. Results {#sec3}
==========

3.1. Dln101 is a human splice-variant of the ghrelin gene with different expression pattern but similar effects over food intake and body weight gain {#sec3.1}
-----------------------------------------------------------------------------------------------------------------------------------------------------

Structurally similar to ghrelin, Dln101 is an acylated 24-amino acid peptide that is derived from a naturally occurring splice variant of human ghrelin. To increase the stability of Dln101 peptide, the ester bond between the serine at position 3 (Ser3) and the n-octanoyl group was modified to an amide bond, resulting in replacement of Ser3 by 2, 3-diaminopropionic acid (DAP) ([Figure 1](#fig1){ref-type="fig"}A). Dln101 mRNA expression pattern also differs from the one observed for ghrelin. Ghrelin is mainly expressed in gastro-intestinal (GI) organs and, to a lower extent, in kidney and neural tissue. Dln101 had low to no expression in the GI tract but displayed elevated expression in kidney and neural tissue ([Figure 1](#fig1){ref-type="fig"}C). When administered to mice for 7 consecutive days, Dln101 displayed an effect similar to ghrelin, promoting increases in bodyweight. We also observed a positive trend (at day 6, *p* = 0.09; at day 7 *p* = 0.056) in cumulative food intake ([Figure 1](#fig1){ref-type="fig"}B).Figure 1**Dln101 is a human splice-variant of the ghrelin gene with different expression pattern but similar effects over food intake and body weight gain**. **(A)** Dln101 and ghrelin peptide sequences. Mature peptides display homology of 57% and same acylation site in the third residue. **(B)** Chronic peripheral (s.c.) injection of Dln101 or ghrelin (7.2 mg/kg) had similar effects on Body Weight Gain and Food Intake in mice. Two-way ANOVA followed by multiple comparisons test; n = 8 per group. **(C)** Human ghrelin gene mRNA splicing and their respective expression pattern. Two splicing patterns of ghrelin mRNA. The boxes represent exons, short boxes represent untranslated sequences, and long boxes represent coding sequences. Top pattern yields mature ghrelin 117 amino acids preproghrelin, while bottom pattern yields Dln. Qualitative RT-PCR was conducted on 6 selected human samples (Stratagene: Kidney, Pancreas, Stomach, Duodenum, Placenta, and non-commercial A172 glioblastoma cell line -- neural tissue). Water was used as negative control. Dln and ghrelin bands are indicated with arrows.Figure 1

Next, we decided to compare acylated Dln101 (henceforth Dln101) and acylated ghrelin (henceforth ghrelin) plasma pharmacokinetic concentrations, following subcutaneous and intraperitoneal administrations as shown in [Table 1](#tbl1){ref-type="table"}. Absorption was rapid across all doses with T~MAX~ at 5 min. Intraperitoneal (i.p.) injections of 1.2 and 7.2 mg/kg of Dln101 raised plasma concentration to peak (C~MAX~) at 36.3 and 588 ng/ml. Ghrelin i.p. injections reached C~MAX~ at 7.5 and 171.4 for 1.2 and 7.2 mg/kg doses, respectively. Subcutaneous (s.c.) injections of Dln101 displayed similar PK parameters when compared to i.p. injections. Increases in both AUC and C~MAX~ were proportional to administered dose and route, with s.c. administrations displaying higher C~MAX~ and AUC for 7.2 mg/kg dosage. Mean half-life of Dln101 ranged between 11.9 and 20.9 min compared to 14.8 for ghrelin.Table 1**Pharmacokinetic profile of Dln101 and ghrelin.** T~MAX~ = time of maximal plasma concentration, C~MAX~ = maximal plasma concentration, AUC~0-∞~ = area under the plasma concentration *vs* time curve from time 0 to infinity, T~1/2~ = half-life.Table 1PEPTIDEDOSE (mg/Kg)ROUTET~MAX~ (min)C~MAX~ (ng/mL)AUC~0-∞~ (ng.min/mL)T~1/2~ (min)Dln1011.2*i.p.*536.362220.97.2588916011.97.2*s.c.*8281610612.6Ghrelin1.2*i.p.*7.5NANA7.2171.44078814.8

3.2. Dln101 protects *SN* DA neurons against MPTP-induced degeneration, inflammation, and increased ROS production {#sec3.2}
------------------------------------------------------------------------------------------------------------------

Initially, we evaluated neuroprotection of *SN* DA neurons by ghrelin and Dln101 by counting *SN* tyrosine hydroxylase-positive (TH^+^) neurons in brain sections from mice injected, s.c., for 10 consecutive days, 15 min before the onset of the dark cycle, with either saline (first and second bar on the graph), ghrelin (15nmoles), or Dln101 (15nmoles). On day 7, animals were challenged with MPTP (60 mg/kg, i.p.), or not (control group). MPTP injection promoted vast nigral degeneration in vehicle-treated animals, with 55.9% reduction in TH^+^ cells, equally mitigated by either ghrelin or Dln101 pre-treatment, with 19.8% and 16% reduction, respectively ([Figure 2](#fig2){ref-type="fig"}A,B). Preservation of motor behavior was evaluated using the accelerating Rotarod test, with vehicle-treated animals used as controls. A shorter latency to fall from the apparatus is indicative of motor impairment, a hallmark of MPTP-treated animals, which displayed a reduction of 42.7% in latency to fall time when compared to controls. Animals that received either ghrelin or Dln101 before MPTP challenge, displayed comparable levels of motor performance, with 16.3 and 16% reduction in latency to fall time respectively, supporting their role as being neuroprotective of the nigrostriatal dopamine system ([Figure 2](#fig2){ref-type="fig"}C). In line with these observations, dopamine levels in dorsal striatum of animals exposed to MPTP displayed a 90% reduction ([Figure 2](#fig2){ref-type="fig"}D). Animals pre-treated with ghrelin or Dln101 showed significantly attenuated dopamine depletion of 60% and 56%, respectively. Moreover, analysis of dopamine turnover products DOPAC and HVA suggests protection of dopamine release in animals pre-treated with ghrelin and Dln101 exposed to MPTP ([Figure 2](#fig2){ref-type="fig"}D).Figure 2**Neuroprotective effect of ghrelin and Dln101 in WT mice**. Mice had daily s.c. administration of saline, ghrelin 15 nM, or Dln101 15 nM 15 min before the onset of dark phase for 10 consecutive days. **(A)** Visualization of TH^+^ cells in DAB immunohistological preparation. Scale bar 100 μm. Parameters from DA cells of the *SN* but not from VTA were analyzed. The distinction was made visually, as indicated. SNc (*Substantia nigra pars compacta*), VTA (Ventral Tegmental Area), ML (Medial Lemniscus). **(B)** Total number of TH^+^ cells in *SN* was evaluated. MPTP-treated animals, pre-treated with saline (gray bars), displayed a reduction in the number of *SN* DA cells when compared to controls (vehicle = 7305 ± 128; MPTP = 3222 ± 200). Animals pre-treated with either ghrelin or Dln101 displayed comparable levels of *SN* DA cell protection (ghrelin = 5857 ± 129, Dln101 = 6139 ± 84, TH^+^ cells); n = 5--10 per group. **(C)** Motor performance was evaluated using the rotarod test. Latency to fall from the apparatus was measured in all groups. MPTP-treated animals, pre-treated with saline (gray bars), displayed a reduction in latency to fall time when compared to controls (vehicle = 88.9 ± 6.4; MPTP = 51.0 ± 5.0, in seconds). Animals pre-treated with either ghrelin or Dln101 displayed comparable levels of motor performance, with a lower reduction in latency to fall time (ghrelin = 74.4 ± 6.4, Dln101 = 74.7 ± 9.2, in seconds); n = 5--11 per group. **(D)** Dopamine, DOPAC and HVA levels were evaluated in dorsal striatum by HPLC-ED; n = 5--11 per group. **(E)** Microglia immunostaining using IBA-1 antibody (green) and *SN* DA cells (TH, red) scale bar 100 μm. Inset showed in higher magnification. Scale bar 10 μm. **(F)** Real-time PCR analysis of proinflammatory markers in midbrain tissue; n = 4 per group. **(G)** DHE staining of ROS in midbrain sections. Cells co-labelled with TH (green) and the ROS probe DHE (red) were analyzed for fluorescence intensity (quantification in the graph). Scale bar 50 μm. N = 4--6 per group **(H)** Real-time PCR analysis of antioxidative enzymes using DAT-Ribotag immunoprecipitated midbrain mRNA. Unpaired t test n = 4 per group. All other data were analyzed using One-way ANOVA test followed by multiple comparisons test.Figure 2

Next, we decided to analyze Dln101 effects over *SN* DA neurons that bring about protection. Based on current literature of PD, we hypothesized that mitigation of MPTP-induced nigral degeneration by Dln101 could be achieved by dampening inflammation, regulating ROS production/detoxification, augmenting midbrain dopamine neuron electrical activity, changes in mitochondria, or any combination of aforementioned effects. Following MPTP exposure, we observed microglial activation using ionized calcium binding adaptor molecule 1 (IBA1) immunostaining ([Figure 2](#fig2){ref-type="fig"}E) and increased levels of gene expression of activation markers, such as the glycoprotein cluster of differentiation (CD) 68 gene, the C-C motif chemokine ligand 2 (CCL-2) gene, and the inflammasome protein Nrlp3 gene. Pro-inflammatory cytokine TNFα gene also displayed increased levels after MPTP exposure. Interestingly, animals pre-treated with Dln101 displayed microglial morphology similar to vehicle-treated animals ([Figure 2](#fig2){ref-type="fig"}E) and no increase in levels of TNFα, CD68, and CCL-2 genes was observed ([Figure 2](#fig2){ref-type="fig"}F). As microglia cells are activated during cellular damage, these results suggest less microglial activation in the *SN* and, therefore, decreased overall dopaminergic cell loss in animals pre-treated with Dln101.

Accumulating evidence indicates that oxidative damage contributes to the cascade of events leading to degeneration of *SN* DA neurons. Evaluation of ROS levels using dihydroethidium (DHE) demonstrated a 7.46 fold increase in ROS (red) production in *SN* DA neurons (TH^+^- green) following MPTP exposure ([Figure 2](#fig2){ref-type="fig"}G). Animals pre-treated with Dln101 displayed reduced levels of ROS (5.25 fold increase). In further investigating mRNA levels of enzymes involved in ROS production and detoxification in *SN* DA neurons using the DAT-ribotag animals, we found upregulation of superoxide dismutase 2 (SOD2) and catalase ([Figure 2](#fig2){ref-type="fig"}H), involved in detoxification of superoxide and peroxide species, respectively. No changes were observed in mRNA levels for glutathione peroxidase. Surprisingly, opposite to what has been described for ghrelin treatment, we found no changes in UCP2 mRNA levels following Dln101 treatment, an increase in mRNA levels of UCP5, and a tendency towards increase in UCP4 ([Figure 2](#fig2){ref-type="fig"}H), both also involved in uncoupling mechanisms in neuronal mitochondria and potential reduction of ROS formation.

3.3. Dln101 and ghrelin have opposite electrophysiological effects over *SN* DA neurons {#sec3.3}
---------------------------------------------------------------------------------------

During the course of characterizing GHSR-mediated effects on *SN* DA neuron physiology, we discovered that the GHSR agonist, ghrelin, and Dln101 had opposite effects on neuronal firing, while both signals act on GHSR receptors. In electrophysiological recordings, ghrelin induced an increase in the firing frequency of *SN* DA neurons, while Dln101 decreased it ([Figure 3](#fig3){ref-type="fig"}A). Neither molecule had an effect on firing activity in *SN* DA cells of GHSR KO animals ([Figure 3](#fig3){ref-type="fig"}B), suggesting the requirement of GHSR for the effect on modulation of neuronal electrical activity. To further investigate whether those effects on electrical activity of *SN* DA neurons in slice preparations for patch clamp analysis would indeed reflect in changes *in vivo* of dopamine release into the dorsal striatum and/or changes in the animals\' locomotor behavior, we evaluated the effect of ghrelin and Dln101 on dopamine release in the dorsal striatum, the synaptic target of *SN* DA neurons. In line with the electrophysiology experiments, 30--45 min after subcutaneous injection, ghrelin induced an increase in dopamine release ([Figure 3](#fig3){ref-type="fig"}C-top) whereas Dln101 induced a decrease when compared to littermates injected with 0.9% NaCl (saline -- CTR) ([Figure 3](#fig3){ref-type="fig"}C-bottom). Again, no change was observed in the dorsal striatum of GHSR KO mice ([Figure 3](#fig3){ref-type="fig"}D). To show specificity of modulation of the dopaminergic system, serotonin release in the dorsal striatum of WT animals was measured under the same conditions and neither ghrelin nor Dln101 induced a change ([Figure 3](#fig3){ref-type="fig"}E).Figure 3**Effects of ghrelin and Dln101 over *SN* DA neuron function of GHSR KO mice and their WT littermates. (A)** Using patch-clamp slice electrophysiology analysis, the firing frequency (generation of action potentials) was recorded in *SN* DA neurons for 15 min followed by acute ghrelin (1 μM) or Dln101 (1 μM) administration. In WT neurons, ghrelin increased (120.3% relative to baseline) neuronal activity whereas Dln101 decreased it (55.5%). **(B)** No effect was observed in GHSR KO animals. Paired t test; n = 4--13 per group. **(C)** Dopamine turnover (DOPAC/DA ratio) was evaluated by HPLC-ED 30 min after s.c. administration of saline (CTR), ghrelin 15 nM, or Dln101 15 nM. In WT mice, ghrelin promoted increased dorsal striatum dopamine release (CTR = 0.040 ± 0.002, Ghrelin = 0.066 ± 0.009, top graph). After Dln101 administration, dopamine release was reduced in dorsal striatum (CTR = 0.038 ± 0.002, Dln101 = 0.005 ± 0.001, bottom graph). Unpaired t tests, n = 4--5. **(D)** Dopamine release in dorsal striatum of GHSR KO animals was unaffected by ghrelin or Dln101. Unpaired t tests, n = 3--4. **(E)** For control purposes, serotonin turnover (5HIAA/5HT) was quantified in dorsal striatum following ghrelin or Dln101 injection and no change was observed. Unpaired t tests, n = 5--7. **(F)** Average locomotor activity was evaluated by infrared monitoring up to 3 h after subcutaneous administration of saline, ghrelin 15 nM, or Dln101 15 nM. Total number of beam breaks on the day of ghrelin/Dln101 administration was subtracted from total number of beam breaks from the day before, when animals received saline (baseline). Ghrelin promoted a tendency to increase average locomotor activity (p = 0.10) whereas Dln101-injected animals had the opposite effect, promoting a substantial decrease in locomotor activity. Paired t test; n = 4 per group. All other data were analyzed using unpaired t tests.Figure 3

The nigrostratal dopaminergic pathway modulates both the direct and indirect pathways of motor control by basal ganglia, and dopamine release in the dorsal striatum leads to increased motor activity. To fully characterize the role of ghrelin and Dln101 in the activation of the nigrostriatal pathway and their effect over locomotor activity, WT mice were monitored using infrared monitors after ghrelin (15 nmoles) or Dln101 (15 nmoles) injection 15 min before the onset of the dark phase. As expected for scenarios of increased electrical activity of *SN* DA neurons and increased dopamine release in the dorsal striatum, animals injected with ghrelin displayed a trend towards increased locomotor activity in comparison to saline-injected mice. The opposite was found in Dln101-injected animals ([Figure 3](#fig3){ref-type="fig"}F).

3.4. Modulation of *SN* DA cell electrical activity does not interfere with MPTP-induced degeneration {#sec3.4}
-----------------------------------------------------------------------------------------------------

The presence of GHSR was protective of *SN* dopamine neurons in the MPTP model regardless of whether the ligand electrically activated (ghrelin) or inhibited (Dln101) the dopamine neurons. We sought to verify whether dopamine neuronal activation or inactivation *per se* would impact *SN* DA neuronal survival upon MPTP-induced cellular stress. To address that, we used mice harboring the dopamine-associated transporter-cre recombinase transgene (DAT-cre), which permits control over neuronal electrical activity, in a cre-dependent fashion (expressed in dopamine neurons). DAT-cre mice were injected bilaterally into the *SN* with excitatory DREADD virus (rAAV5-hSyn-DIO-hM3Dq-mCherry; DAT-*SN*^hM3q^) or inhibitory DREADD virus (rAAV9-hSyn-DIO-KORD-IRES-mCitrine; DAT-*SN*^KORD^) (UNC Vector Core). DREADD receptors are only expressed in cre recombinase-positive cells, and, due to spatial localization of the viral injection, this procedure allows the expression of DREADDs exclusively in *SN* DA neurons ([Figure 4](#fig4){ref-type="fig"}A). Mice were then injected subcutaneously with either clozapine-N-oxide (CNO, excitatory DREADD agonist) or 0.9% saline vehicle control; or salvinorin B (inhibitory DREADD agonist) or DMSO vehicle control, permitting chemicogenetic excitation or inhibition of *SN* DA cells with CNO or salvinorin B, respectively. To confirm proper control of activity of *SN* DA neuronal population, we evaluated dopamine release in the dorsal striatum and locomotor activity of DAT-*SN*^hM3q^ ([Figure 4](#fig4){ref-type="fig"}B-top) and DAT-*SN*^KORD^ ([Figure 4](#fig4){ref-type="fig"}B-bottom).Figure 4**Modulation of electrical activity of *SN* DA neurons and its effects on survival, dopamine release in dorsal striatum, and locomotor activity in DAT-cre-ribotag mice**. **(A)** GHSR-mediated protection of substantia nigra dopamine neurons by ghrelin or Dln101 occurs despite their opposite effects on neuronal electrical activity. To address whether modulation of electrical activity is sufficient or necessary for neuroprotection, we used DREADDs to evaluate neuroprotection in scenarios of controlled neuronal firing. **(B)** Dopamine turnover (DOPAC/DA ratio) and locomotor activity in DAT-cre-ribotag mice was evaluated 30--45 min after subcutaneous administration of vehicle (CTR), CNO (0.3 mg/kg) or Salvinorin B (5 mg/kg). Excitatory DREADD activation with CNO promoted elevated dopamine release in dorsal striatum in comparison to saline (CTR = 1.00 ± 0.13, CNO = 1.77 ± 0.08), n = 3. Inhibitory DREADD activation with Salvinorin B produced a tendency towards decreased dopamine release (CTR = 1.00 ± 0.47, Salvinorin B = 0.55 ± 0.16), n = 5. Animals had their locomotor activity recorded for 10 min. CNO promoted a tendency towards increased locomotor activity, while Salvinorin B decreased it (CTR = 10.87 ± 2.01, CNO = 13.62 ± 0.90) and (CTR = 13.37 ± 1.61, Salvinorin B = 6.67 ± 1.17). Unpaired t test; n = 3--10 per group. **(C)** Total number of TH^+^ cells in *SN* was evaluated in WT animals with expression of excitatory DREADD. CNO (0.3 mg/kg) was injected daily using the same routine used for ghrelin and Dln101 administration, or chronically released using osmotic minipump placed in the interscapular space. MPTP administration promoted vast nigral degeneration that was not prevented by the excitatory DREADD agonist, in any of the delivery formats. **(D)** Total number of TH^+^ cells in *SN* was evaluated in WT animals with expression of inhibitory DREADD. Salvinorin B (5 mg/kg) was injected or chronic released using osmotic minipump. **(E)** Total number of TH^+^ cells in *SN* was evaluated in GHSR KO animals with expression of excitatory DREADD. **(F)** Total number of TH^+^ cells in *SN* was evaluated in GHSR KO animals with expression of inhibitory DREADD. **(G)** Ghrelin-induced increase in dopamine release in dorsal striatum was prevented with injection of Salvinorin B in animals with expression of inhibitory DREADD. Likewise, Dln101-induced decrease in dopamine release in dorsal striatum was prevented with injection of CNO in animals with expression of excitatory DREADD. **(H)** Dln101 and ghrelin displayed their neuroprotective effect even with neutralization of their effects on neuronal firing. Data from C to H were analyzed using One-way ANOVA test followed by multiple comparisons test, n = 6--8 per group.Figure 4

To check neuroprotection of *SN* DA cells after MPTP (60 mg/kg) insult, DAT-*SN*^hM3q^ animals were administered subcutaneously daily for 7 consecutive days, 15 min before the onset of the dark cycle, with either vehicle (first and third bar), CNO (second and fourth bar), or had an osmotic minipump filled with CNO solution implanted (fifth bar) and then challenged with MPTP ([Figure 4](#fig4){ref-type="fig"}C). After MPTP, animals were maintained in injection protocol for additional 3 days (10 days total). Similarly, DAT-*SN*^KORD^ animals received either vehicle (first and third bars), Salvinorin B (second and fourth bars), or had an osmotic minipump filled with Salvinorin B solution implanted (fifth bar) ([Figure 4](#fig4){ref-type="fig"}D). The exact same procedure was performed in GHSR-KO animals injected with DREADD virus ([Figure 4](#fig4){ref-type="fig"}E,F). Control animals underwent the same injection routine but did not receive MPTP at the end of the 7 consecutive days. Quantification of *SN* DA cells (TH^+^ cells) showed that neither increase nor decrease of *SN* DA cell electrical activity had any neuroprotective effect and both WT and GHSR-KO animals displayed the exact same level of MPTP-induced degeneration as observed in control animals. Additionally, we decided to use the DREADD approach to neutralize the effect of ghrelin and Dln101 over the electrical activity of *SN* DA cells and verify the impact on the neuroprotection observed with these two molecules ([Figure 4](#fig4){ref-type="fig"}A). DAT-*SN*^KORD^ animals treated with ghrelin and DAT-*SN*^hM3q^ animals treated with Dln101 had their electrical activity effect neutralized with Salvinorin B or CNO, respectively. Analysis of dopamine release in the dorsal striatum confirmed neutralization ([Figure 4](#fig4){ref-type="fig"}G). However, neutralization of the electrical activity did not interfere with the neuroprotective effect of both ghrelin and Dln101 ([Figure 4](#fig4){ref-type="fig"}H). Altogether, our data suggest that modulation of electrical activity of *SN* DA cells is completely irrelevant for acyl-ghrelin or Dln101-mediated neuroprotection in the MPTP-induced neurodegeneration model.

3.5. Dln101 and ghrelin have opposite effects over *SN* DA neuron mitochondria {#sec3.5}
------------------------------------------------------------------------------

Mitochondrial dynamics has a direct impact over mitochondrial functions and thus is of central importance for the pathophysiology of neurodegenerative processes. However, the *in vivo* significance of changes in mitochondrial dynamics in the context of nigrostriatal dopaminergic cells has remained undetermined. We decided to evaluate mitochondrial morphology following ghrelin and Dln101 treatment and its impact on neuroprotection of *SN* DA cells using electron microscopy. Initially, we compared animals treated with either Dln101 or ghrelin for 10 consecutive days under the same protocol used to achieve neuroprotection. Analysis of the distribution of mitochondrial area demonstrated a higher percentage of bigger mitochondria in *SN* DA cells from Dln101-treated animals, compared to controls, shifting the histogram curve to the right and indicative of increased fusion ([Figure 5](#fig5){ref-type="fig"}A,B). Average mitochondrial area was also increased following Dln101 treatment ([Figure 5](#fig5){ref-type="fig"}C). No change in area was observed in the ghrelin-treated group ([Figure 5](#fig5){ref-type="fig"}A--C). Mitochondrial cytoplasmic coverage was not changed in the Dln101 group but was increased in the ghrelin group, suggesting increased mitochondrial biogenesis promoted by ghrelin ([Figure 5](#fig5){ref-type="fig"}D), as previously described [@bib12]. Next, we decided to evaluate changes in mitochondrial morphology following MPTP exposure (15 mg/kg) and how pre-treatment with Dln101 would impact mitochondrial changes. Animals were euthanized at 2 different time points: 4 h, and 1 day after MPTP exposure. At the 4-hours\' time point, MPTP-treated animals displayed a shift to the left in the mitochondrial histogram curve and a decrease in average mitochondrial area, all indicative of increased fission ([Figure 5](#fig5){ref-type="fig"}E--G, red). No change in mitochondrial cytoplasmic coverage was observed ([Figure 5](#fig5){ref-type="fig"}H). Surprisingly, 1 day after MPTP exposure, we actually observed a shift to the right in the mitochondrial histogram curve and an increase in average mitochondrial area ([Figure 5](#fig5){ref-type="fig"}E--G, orange). However, a marked decrease in mitochondrial cytoplasmic coverage was observed ([Figure 5](#fig5){ref-type="fig"}H), indicative of degeneration of small mitochondria and preservation of bigger mitochondria, shifting the population towards bigger mitochondria but in lower number. Interestingly, animals pre-treated with Dln101 before MPTP displayed a more pronounced shifting to the right on the mitochondrial histogram curve at 1-day time point, with associated increase in the average area of remaining mitochondria ([Figure 5](#fig5){ref-type="fig"}E--G, green). Additionally, no changes in cytoplasmic coverage were observed. Taken together, our working hypothesis was that MPTP treatment initially leads to mitochondrial fragmentation, with following degeneration of small and preservation of bigger mitochondria. Dln101 treatment induces fusion of mitochondria and therefore protects mitochondria against MPTP-induced fragmentation and degeneration.Figure 5**Effect of ghrelin and Dln101 on mitochondrial dynamics of WT *SN* DA neurons**. **(A)** Representative EM pictures of WT *SN* DA cells under various treatments, with drawing of overall mitochondrial distribution in the representative cell. Scale bar = 1 μm **(B)** Cumulative probability distribution for mitochondrial area (vehicle = black, Dln101 = purple, ghrelin = red). Kolmogorov--Smirnov test, n = 315--555 per group. **(C)** Mitochondrial average area (vehicle = 0.143 ± 0.004, Dln101 = 0.181 ± .006, ghrelin = 0.138 ± .004, in μm^2^). **(D)** Mitochondrial cytoplasmic coverage (vehicle = 9.94% ± 1.1, Dln101 = 11.2% ± 0.75, ghrelin = 13.05% ± 0.79, as percentage of total cytoplasm area). Area and coverage were analyzed using One-way ANOVA followed by multiple comparisons test; n = 315--555 per group. **(E)** MPTP-induced mitochondrial fragmentation and degeneration in *SN* DA neurons. Representative EM pictures of *SN* DA cells. **(F)** Cumulative probability distribution for mitochondrial area (vehicle = blue, MPTP 4h = red, MPTP 1day = orange, Dln101 + MPTP 1day = green). **(G)** Mitochondrial average area (vehicle = 0.143 ± 0.004, MPTP 4h = 0.112 ± 0.006, MPTP 1day = 0.176 ± 0.006, Dln101 + MPTP 1day = 0.234 ± 0.009). **(H)** Mitochondrial cytoplasmic coverage (vehicle = 9.94% ± 1.1, MPTP 4h = 8.66% ± 0.68, MPTP 1day = 6.144% ± 0.51, Dln101 + MPTP 1day = 8.14% ± 0.55). Kolmogorov--Smirnov test on cumulative distribution, One-way ANOVA on G and H; n = 102--473 per group. **(I)** Real-time PCR data of genes coding mitochondrial fission (FIS-1, MFF, DRP-1) and fusion proteins (MFN 1, MFN 2, OPA-1) at 4h time point. One-way ANOVA test followed by multiple comparisons test; n = 4--7 per group.Figure 5

To support the idea of Dln101-induced mitochondrial fusion, we decided to evaluate the expression of several genes related to the control of mitochondrial dynamics. Using DAT-cre-ribotag animals, we compared the gene expression between controls, Dln101, ghrelin, and MPTP-treated (all after 4h) animals. For genes involved with mitochondrial fission (Fis-1, Mff and Drp-1), no change was observed with Dln101 treatment. Ghrelin treatment led to an increase in Mff and MPTP treatment increased expression of Drp-1, the main regulator of mitochondrial fission. For genes related to mitochondrial fusion (Mitofusin 1 and 2, Opa-1), Dln101 treatment led to an increase in mfn 2 expression, but not in mfn 1. No change in these two genes was observed with ghrelin treatment. Inversely, MPTP treatment led to a markedly decrease in both mitofusins expression. Taken together, real-time pcr data indeed support the notion of increased mitochondrial fission following MPTP treatment and increased mitochondrial fusion following Dln101 treatment ([Figure 5](#fig5){ref-type="fig"}I). Moreover, data suggests that mfn2 might have an important role in this process.

3.6. Knockout of mitochondrial fusion protein 2 (MFN 2) blocks DLN101-induced mitochondrial fusion in *SN* DA neurons {#sec3.6}
---------------------------------------------------------------------------------------------------------------------

To determine if mfn2 is indeed a key factor controlling mitochondrial fusion and Dln101-mediated neuroprotection in *SN* DA cells, we generated mice with tamoxifen-induced deletion of mfn 2 gene in dopamine cells (iCre-DAT^MFN2\ KO^). Mice were allowed normal development and had their series of tamoxifen injections between 4 and 6 weeks of age. Deletion of mfn2 gene *per se* in dopamine cells did not alter dorsal striatum dopamine levels, number of *SN* DA cells, locomotor activity ([Figure 6](#fig6){ref-type="fig"}A--C), or generated any noticeable behavioral alteration on these animals, checked until 4 months after tamoxifen exposure. Electron microscopy analysis of mitochondria of iCre-DAT^MFN2\ KO^ *SN* DA cells revealed no changes in mitochondrial morphology, area, or coverage ([Figure 6](#fig6){ref-type="fig"}D,E). However, when iCre-DAT^MFN2\ KO^ animals were treated with Dln101, no increased rate of fusion was observed ([Figure 6](#fig6){ref-type="fig"}F--H).Figure 6**Mitofusin 2 deletion in DA neurons**. **(A)** HPLC measurement of dorsal striatum dopamine levels (iCre-DAT^WT^ = 184.9 ± 9.1, iCre-DAT^MFN2KO^ = 139.4 ± 30.5, in ng/mg of tissue protein) Unpaired *t*-test*,* n = 4--5. **(B)***SN* DA neuron number did not differ between control groups and iCre-DAT^MFN2KO^ animals (Controls = 7532 ± 62, 7482 ± 198, 7464 ± 86; iCre-DAT^MFN2KO^ = 7912 ± 383), One-way ANOVA*, n* = 3--7. **(C)** Open field locomotor behavior analysis (B = before, A = after tamoxifen injections; iCre-DAT^WT^ grey bars and iCre-DAT^MFN2KO^ black bars; Total distance travelled (iCre-DAT^WT^, B = 8.0 ± 1.7, A = 8.2 ± 1.9; iCre-DAT^MFN2KO^, B = 10.0 ± 1.0, A = 7.4 ± 0.91; in meters). Average speed (iCre-DAT^WT^, B = 0.026 ± 0.005, A = 0.027 ± 0.005; iCre-DAT^MFN2KO^, B = 0.033 ± .003, A = 0.025 ± 0.003; in meters/second). Total time mobile (iCre-DAT^WT^, B = 134 ± 19, A = 136 ± 20; iCre-DAT^MFN2KO^, B = 138 ± 14, A = 132 ± 13, in seconds), total behavior test time was 300 s. Two-way ANOVA analysis retrieved no statistically significant differences, n = 11--14. **(D)** Representative EM pictures of *SN* DA cells of control (WT, either cre negative or iCre-DAT^MFN2\ fl/fl^ animals that did not receive tamoxifen) and iCre-DAT^MFN2KO^ animals, with drawing of overall mitochondrial distribution in the representative cell. **(E)** Cumulative probability distribution for mitochondrial area (cre negative = grey, no tamoxifen = black, iCre-DAT^MFN2KO^ = red). No change was observed between groups. Kolmogorov--Smirnov test, n = 421--723 per group. **(F)** Dln101 does not induce mitochondrial fusion in iCre-DAT^MFN2KO^ animals. Representative EM pictures of *SN* DA cells. **(G)** Differently of what was observed in WT animals, Dln101 treatment did not induce a shift to the right in the cumulative distribution curve, suggesting no increased rate of mitochondrial fusion observed in iCre-DAT^MFN2KO^ animals. **(H)** No change in mitochondrial average area, or mitochondrial cytoplasmic coverage was observed with Dln101 treatment in iCre-DAT^MFN2KO^ animals. One-way ANOVA test followed by multiple comparisons test, n = 421--723 per group.Figure 6

3.7. Knockout of MFN 2 prevents DLN101 neuroprotective effect and, in combination with MPTP, induces an aberrant mitochondria phenotype *SN* DA cells {#sec3.7}
-----------------------------------------------------------------------------------------------------------------------------------------------------

Lack of increased fusion in the Dln101-treated iCre-DAT^MFN2\ KO^ animals was correlated with absence of neuroprotection against MPTP, as evaluated by total TH^+^ cell number in *SN* of those animals ([Figure 7](#fig7){ref-type="fig"}A), and motor performance in the rotarod test ([Figure 7](#fig7){ref-type="fig"}B). In fact, MPTP-treated iCre-DAT^MFN2\ KO^ animals displayed loss of small mitochondria, leading to an increase in average mitochondrial area, but to a decrease in both total number of mitochondria per cell and mitochondrial cytoplasmic coverage ([Figure 7](#fig7){ref-type="fig"}D). This was similar to what was observed in WT animals ([Figure 5](#fig5){ref-type="fig"}E), after 1 day of MPTP-exposure. Noteworthy, in MPTP-treated iCre-DAT^MFN2\ KO^ animals, these changes in mitochondrial content happened already 4 h after MPTP challenge. Finally, swollen mitochondria, with unidentifiable cristae, typical of dysfunctional, mitophagy-prone mitochondria was predominant in iCre-DAT^MFN2\ KO^ animals after 3 days of MPTP challenge ([Figure 7](#fig7){ref-type="fig"}C), leading to a further increase in both average mitochondrial area and coverage ([Figure 7](#fig7){ref-type="fig"}D). Supporting the notion of severe loss of mitochondrial content, we observed a continuous drop in the average number of mitochondrial units per cell following MPTP exposure ([Figure 7](#fig7){ref-type="fig"}D).Figure 7**Mitofusin 2 deletion in DA neurons prevents Dln101 neuroprotective effect**. **(A)** Visualization of TH^+^ cells in DAB immunohistological preparation. Scale bar 100 μm. Stereological analysis indicates Dln101 administration did not mitigate MPTP-induced degeneration of *SN* DA cells in iCre-DAT^MFN2KO^ animals (iCre-DAT^MFN2KO^ = 7912 ± 383, iCre-DAT^MFN2KO^ + MPTP = 3205 ± 390, iCre-DAT^MFN2KO^ + Dln101 + MPTP = 3375 ± 329). One-way ANOVA test followed by multiple comparisons test, n = 4--6. **(B)** Dln101 treatment in iCre-DAT^MFN2KO^ animals did not prevent MPTP-induced decreased motor performance, assessed in the rotarod test (latency to fall, iCre-DAT^MFN2KO^ = 71.5 ± 5.1, iCre-DAT^MFN2KO^ + MPTP = 45.3 ± 4.7, iCre-DAT^MFN2KO^ + Dln101 + MPTP = 42.0 ± 6.9; in seconds). One-way ANOVA test followed by multiple comparisons test, n = 5--10. **(C)** Representative EM pictures of *SN* DA cells of iCre-DAT^MFN2KO^ animals after MPTP exposure. MPTP administration induced aberrant mitochondria phenotype, with surviving neurons displaying bigger and rounder mitochondria, indicated with arrowheads. Remaining mitochondria showed circular cristae, and abnormal inner membrane structures. **(D)** Aberrant mitochondria phenotype reflected in much higher average mitochondrial area (iCre-DAT^MFN2KO^ = 0.163 ± 0.005, iCre-DAT^MFN2KO^ + MPTP 4h = 0.179 ± 0.004, iCre-DAT^MFN2KO^ + MPTP 3days = 0.287 ± 0.006), but fewer mitochondrial units per cell (iCre-DAT^MFN2KO^ = 80 ± 12, iCre-DAT^MFN2KO^ + MPTP 4h = 52 ± 6, iCre-DAT^MFN2KO^ + MPTP 3days = 29 ± 3). Finally, mitochondrial coverage was drastically increased after 3 days of MPTP exposure, indicating the fewer but enormous remaining mitochondria doubled the covered cytoplasmic area when compared to the other groups (iCre-DAT^MFN2KO^ = 9.35% ± 0.56, iCre-DAT^MFN2KO^ + MPTP 4h = 10.22 ± 0.69, iCre-DAT^MFN2KO^ + MPTP 3days = 23.32 ± 4.21). One-way ANOVA test followed by multiple comparisons test, n = 421--1456.Figure 7

4. Discussion {#sec4}
=============

Ghrelin is mainly produced in the X/A-like gland cells of the gastric fundus mucosa [@bib44] and, to a lesser degree, in the intestines, pancreas, gall bladder, liver, gonads, and breasts [@bib45]. Ghrelin peptide is formed after post-translational processing of the 117-amino-acid peptide preproghrelin. Then, native ghrelin peptide is subject to a unique modification consisting of acylation (addition of an octanoyl group) of the third serine residue (Ser3), a process well conserved among mammalian species [@bib46]. The enzyme responsible for ghrelin acylation, before its secretion, is known as ghrelin-O-acyl-transferase (GOAT), and is predominantly expressed in gastrointestinal organs [@bib47], [@bib48]. According to its acylation status, the peptide can be termed des-acyl or acyl ghrelin. De-acylation process is performed by esterases, including acyl-protein thioesterase-1/lysophospholipase-1 (APT-1), thought to be mainly responsible for ghrelin de-acylation *in vivo* [@bib49].

Physiological action of acyl ghrelin gene products specifically in the midbrain has been matter of debate as ghrelin does not seem to be expressed in the central nervous system [@bib50], [@bib51] despite immunolabeling in arcuate nucleus neurons [@bib52], [@bib53], and some cells around the third ventricle [@bib54]. On one hand, although only acyl ghrelin is able to activate GHSR, 66--94% of circulating ghrelin is actually found in the des-acyl form [@bib55], [@bib56], [@bib57], due to the activity of esterases and APT-1 [@bib49]. In addition, ghrelin has a limited capacity to cross the blood-brain-barrier [@bib58]. On the other hand, Dln101 emerges as a relevant candidate to maintain GHSR activation due to its increased stability in the acylated residue.

Des-acyl ghrelin is the predominant form of ghrelin, but the lack of acylation precludes it from binding to GHSR and subsequent receptor activation. Despite this, there are several reports describing des-acyl ghrelin\'s biological effects, including neuroprotection [@bib59] and attenuation of proinflammatory cytokines release [@bib60]. Despite the biological importance of des-acyl ghrelin has started to be elucidated, chronic administration of des-acyl ghrelin was shown inefficient in mitigating MPTP-induced *SN* DA neuronal degeneration in ghrelin KO animals [@bib61], suggesting that the neuroprotective effect of ghrelin over *SN* DA cells indeed requires GHSR activation. Another possible explanation for midbrain action of ghrelin gene products is based on the local activity of GOAT [@bib62], which mRNA has been shown to have a broad expression among tissues [@bib63], including the central nervous system [@bib64], [@bib65]. This fact supports the idea that ghrelin gene products could potentially be acylated *in situ,* permitting local activation of GHSR [@bib66].

The potential therapeutic actions of GHSR in the central nervous system has been in the limelight lately. Peripheral administration of GHSR agonists have been shown to inhibit oxidative stress, apoptosis, proinflammatory cytokine production, microglia activation, mitochondrial dysfunction, and excitotoxicity both *in vivo* and *in vitro* [@bib16], [@bib67], [@bib68], [@bib69], [@bib70], [@bib71], as well as exert neuroprotective effects against hippocampal and cortical neuronal death [@bib68], [@bib72], [@bib73], [@bib74]. Through these actions, GHSR has thus been linked to neuroprotection in several CNS diseases such as stroke [@bib75], Alzheimer disease [@bib72], [@bib76], Parkinson disease [@bib11], [@bib12], [@bib13], [@bib69], [@bib77], multiple sclerosis [@bib78], [@bib79], epilepsy [@bib80], [@bib81], and spinal cord injury [@bib82]. Nevertheless, GHSRs have been shown to display higher constitutive basal activity in the absence of ligand [@bib83], suggesting that (1) GHSR-mediated pathways do not need acyl ghrelin gene products to be activated but are modulated by them; (2) the existence of other(s) endogenous ligand(s) able to regulate GHSR activity in the midbrain and other brain areas.

In different cell types and tissues, acyl-ghrelin binds GHSR to activate several intracellular cascades, including ERK 1/2, PI3K/Akt/mTOR, and AMPK signaling pathways, thus mediating different physiological functions. The first described pathway associated with GHSR activation was the inositol 1,4,5-trisphosphate/diacylglycerol (IP3/DAG) pathway, leading to GH release in the anterior pituitary. In other non-neuronal tissues and cell types, the binding of acyl-ghrelin to GHSR activates either the phospholipase C/inositol trisphosphate or the adenylate cyclase/protein kinase A pathways, resulting in an increase in intracellular calcium levels. These activation of these different signaling pathways could be due to different endogenous ligands, differential concentration of acyl ghrelin [@bib84], and/or differential GHSR dimerization to other receptors (as described for dopamine, serotonin, melanocortin receptors, among others) [@bib85], [@bib86], [@bib87], [@bib88]. In *SN* DA cells, mitochondrial function is regulated to some extent by 5′-AMP-activated protein kinase (AMPK), a ubiquitous enzyme that is considered a master sensor of intracellular energy stress that plays a crucial role in adaptive responses to falling energy levels (e.g., from low nutrient availability or cellular stress). AMPK signaling is activated by GHSR and declines in PD patients [@bib89]. Ghrelin-mediated activation of AMPK is associated with neuroprotection of *SN* DA cells [@bib13], [@bib14]. Thus, activating AMPK may be an effective neuroprotective strategy to help restore energy balance and redox homeostasis in *SN* DA neurons, but other signaling pathways might also be involved in GHSR-mediated neuroprotection and must be considered. GHSR-mediated activation of AMPK is also observed in other brain regions, including the arcuate nucleus of the hypothalamus [@bib90]. Further characterization of GHSR-mediated signaling pathways is required to support the development of clinical therapeutics targeting GHSR in *SN* DA cells to promote survival.

Oxidative stress, reactive gliosis, and T-cell infiltration are major pathological features in human PD and are recapitulated in the mouse MPTP model [@bib91]. Oxidative stress defines an imbalance between the levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) produced and the ability of a biological system to detoxify those reactive intermediates. Generation of ROS and RNS involves the activity of mitochondria and are impacted by mitochondrial dynamics. In *SN* DA neurons, oxidative stress can not only compromise protein function but also generate lipid peroxidation [@bib92] and DNA fragmentation, ultimately leading to cell death. In addition, impairment of dopamine synthesis has been observed as a result of oxidation of tyrosine hydroxylase (TH) in the MPTP model [@bib93].

In PD, the roles of oxidative stress and reactive gliosis are supported by postmortem brain tissue analyses (reviewed in [@bib91]). Overall, activated glial cells contribute to increase local oxidative stress [@bib94] and increase proinflammatory cytokine production [@bib91]. Reactive gliosis happens as a consequence of cellular stress and can be divided in two major features: microglia activation and reactivation of astroglia. Specifically in the MPTP model, microglial activation precedes the loss of DA neurons and upreglation of proinflammatory cytokines [@bib95]. Interventions that halt microglial activation have a direct impact on *SN* DA neuroprotection [@bib96]. Reactive astrogliosis and T-cell infiltration in the *SN* are also present in the MPTP model [@bib97], [@bib98], and neuroprotection of *SN* DA cell is achieved with strategies that tackle either one of those features [@bib99], [@bib100], [@bib101]. Here, we demonstrated that Dln101 treatment was correlated with decreases in TH^+^ cell oxidative stress, and microglia activation, as measured by decreased CD68 expression in *SN* region, similar to observed in interventions in monkeys [@bib102]. We also reported prevention of upregulation of proinflammatory genes such as TNFα and the inflammasome component Nrlp3, both of which have been associated with MPTP-induced loss of *SN* DA neurons [@bib103], [@bib104]. Moreover, Dln101 ability to activate GHSR might have a deeper relevance to neuroprotection beyond regulation of mitochondrial dynamics, once GHSR signaling has been linked to negative control of neuroinflammation [@bib104], [@bib105], which is believed to sustain and exacerbate the loss of the DA neurons in PD. Taken together, our data suggest that Dln101 can act in different components of the pathophysiology of *SN* DA neurodegeneration, perhaps providing a better outcome in clinical therapies for PD.

Another key component of proper DA cell physiology is the basal firing activity of *SN* DA neurons, which maintains extracellular levels of dopamine in the dorsal striatum that are essential for voluntary movement [@bib106]. Changes in *SN* DA neuron activity directly impacts the amount of dopamine released in target areas and are largely observed in PD subjects [@bib107] as well as in PD animal models and may occur in the absence of changes in other indirect markers of DA neuron function (e.g. neuron number, DA content) [@bib108], [@bib109].

The proper control of *SN* DA cell electrical activity is of crucial importance because, on one hand and despite the yet elusive mechanism underlying such effect and identification of all cell types involved [@bib110], augmentation of electrical activity of *SN* DA neurons is thought to be neuroprotective, as increased survival of DA cells has been reported with the use of depolarizing agents such as veratridine [@bib19] and K^+^ [@bib111]. Also in line with these observations, prospective cohort and case--control studies have identified tobacco smoking as the most significant protective factor against the risk of developing PD, decreasing it by 60% in active cigarette smokers in comparison to those who never smoked [@bib112], [@bib113]. The mechanisms involved includes reinforcing cholinergic stimulation of *SN* DA neurons with nicotine, which also showed to be protective in mouse and monkey MPTP models [@bib114], [@bib115], [@bib116]. Consistently, degeneration of DA neurons has been observed in situations of diminished electrical activity [@bib117], [@bib118], including the use of MPTP, which is linked to the activation of KATP channels and consequently silencing of *SN* DA neurons [@bib119]. Interestingly, KATP channels-mediated hyperpolarization of *SN* DA neurons induced by mitochondrial dysfunction was mediated by mitochondrial reactive oxygen species (ROS) [@bib120]. These data suggest that ROS could possibly participate in the demise of *SN* DA neurons by rendering them electrically inactive [@bib121].

One another hand, *SN* DA neuron activity and dopamine release relies on a controlled modulation of cytosolic calcium levels [@bib122]. Overactivation of *SN* DA cells leads to excitotoxicity, causing mitochondrial dysfunction and ultimately neuronal degeneration. Therefore, the fine balance between excitation/inhibition is mandatory for proper *SN* DA cell function. Based on that, we decided to investigate effects of electrical activity *per se* on *SN* DA neuroprotection but also on GHSR-mediated neuroprotection. Our data suggest that, at least for the acute mouse MPTP model, modulation of electrical activity is not associated with neuroprotection and, in fact, is not required for GHSR-mediated ghrelin and Dln101 neuroprotection.

Mitochondrial dynamics are tightly coordinated in association with the cell cycle and state, with complex structural and functional interactions leading to fusion and fission of mitochondria to alter the balance of oxidative phosphorylation, rescue damaged mitochondria and regulate reactive oxygen species production. Mitochondrial dynamics are also central to the pathogenesis of idiopathic and toxin-induced cases of PD, as well as several monogenic familial PD forms. Mitochondrial length is the result of competitive balance between GTPase dynamin-like proteins mediators of mitochondrial fusion and fission. Mitofusin 1 (MFN1) and 2 (MFN2), located in the outer mitochondrial membrane, and optic atrophy protein 1 (OPA1), in the inner membrane, regulate mitochondrial fusion whereas dynamin-related protein 1 (DRP1) regulates mitochondrial fission; among other supporting proteins involved [@bib27], [@bib28]. Disruption of mitochondrial fission leads to an extensively interconnected and collapsed mitochondrial network, while defects in mitochondrial fusion lead to mitochondrial fragmentation and loss of mitochondrial DNA. As a promoter of mitochondrial fusion, Dln101 is thought to facilitate the exchange of mitochondrial DNA, protein components, and metabolites required for mitochondrial function, conferring increased resilience against MPTP-induced cellular stress. Efficient mitochondrial fusion is important for cell viability, because cells defective in fusion exhibit reduced growth, decreased mitochondrial membrane potential (ΔΨ~m~), and defective respiration, resulting in impaired cellular energy metabolism [@bib123], [@bib124], exactly as observed in patients with PD [@bib125], in both sporadic and genetic forms of the disease [@bib126].

In fact, changes in mitochondrial dynamics directly affects many things including cellular metabolism [@bib127], mitochondrial mass and turnover [@bib128], mitochondrial transport, and calcium buffering [@bib129]. Nigrostriatal DA neurons seem to have a preferential susceptibility to loss of Mfn2 when compared to VTA DA neurons [@bib130]. Although a specific mitochondrial fusion or fission protein has not been implicated in classic PD, recent data suggest that impaired mitochondrial fusion due to mutations in Opa1 cause parkinsonism in the absence of clinically significant optic atrophy [@bib131]. Furthermore, it is well known that α-synuclein and MPTP cause fragmentation of mitochondria [@bib132]. Taken together, these studies support the notion that interventions to increase mitochondrial fusion are crucial to re-establish proper *SN* DA neuronal function and avoid neurodegeneration, as demonstrated in [@bib133], [@bib134]. Moreover, Rappold and colleagues [@bib134] suggest that increased mitochondrial fusion not only can be a strategy to prevent neurodegeneration but also can be used to restore proper function of remaining cells, as impairment in mitochondrial dynamics also disrupts synaptic release of dopamine. Spared TH^+^ cells in PD patients and animal models of PD after establishment of Parkisonism could benefit from mitochondrial fusion inducing agents to re-establish proper synaptic dopamine release and thus ameliorate the symptoms of PD.

Finally, disruption of cellular metabolism is a key feature of PD, with both α-synuclein and PD-related neurotoxins such as MPTP acting as disruptors [@bib135], [@bib136]. Bioenergetic failure produced by these and other factors may also contribute to the degeneration of vulnerable neurons, such as SN DA cells. Dopamine neurons of the *SN* are particularly vulnerable to energy failure because of their substantial energy demands. Neurons in general consume a huge amount of energy in order to maintain the ionic gradient across their plasma membrane. SN DA neurons have long unmyelinated axons and extensive arborization making their energy demands especially high [@bib137], [@bib138]. Furthermore, they exhibit pacemaking activity that maintains basal DA tone across an expansive region, increasing their energy demands even further [@bib139]. Neurons do not store glycogen so they are especially sensitive to fluctuations in energy demand and reliant on neighboring astrocytes to provide nutrients [@bib140]. Unfortunately, *SN* DA neurons have relatively few surrounding astrocytes to provide supplementary energy [@bib140]. Thus, the nigrostriatal DA system is probably the most vulnerable neuronal population to compromised bioenergetic status [@bib141], becoming very sensitive to changes in mitochondrial dynamics that impact oxidative capacity and cellular bioenergetics.

Author contribution {#sec5}
===================

BS, MN, ZWL, XBG, LM, and TLH designed the experiments. BS, CN, MN, DC, ZWL, XBG, JDE, and LM performed experiments. BS, LM, and TLH designed the project and wrote the paper.

Conflict of interest {#appsec1}
====================

The authors declare no conflict of interest regarding studies of this paper.

This study was supported by NIH grants AG052005, AG052986, AG051459, DK111178 and NKFI-126998 from the Hungarian National Research, Development and Innovation Office (T.L.H), and the Michael J. Fox Foundation.

B.S. and M.N. are recipients of the Science without Borders fellowships from The Brazilian Federal Agency for Support and Assessment of Post-graduate Education (CAPES) and from the National Council for Scientific and Technological Development (CNPq), respectively.
